



## Editor

Josef S Smolen

## Associate Editors

Francis Berenbaum  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Kimme Hyrich  
Rik Lories  
Iain McInnes  
Thomas Pap  
David Pisetsky  
Désirée van der Heijde  
Kazuhiko Yamamoto

## Editorial office

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 3655 5889  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)

**Disclaimer:** The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

**Copyright:** © 2021 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

*ARD* is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases*, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

## Editorials

**1249** SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future  
*L Winthrop, R J Whitley, D Aletaha*

**1252** Call for emergency action to limit global temperature increases, restore biodiversity and protect health

*L Atwoli, A H Baqui, T Benfield, R Bosurgi, F Godlee, S Hancocks, R Horton, L Laybourn-Langton, C A Monteiro, I Norman, K Patrick, N Praities, M GM O Rieker, E J Rubin, P Sahni, R Smith, N J Talley, S Turale, D Vázquez*

## Reviews

**1255** Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases

*M A Friedman, J R Curtis, K L Winthrop*

**1266** Message from the new EULAR President and Steering Group

*A Iagnocco, D Aletaha, X Baraliakos, I B McInnes*

**1268** Preclinical models of arthritis for studying immunotherapy and immune tolerance

*G R Meehan, R Thomas, S Al Khabouri, P Wehr, C MU Hilken, D C Wraith, D Sieghart, M Bonelli, G Nagy, P Garside, D F Tough, H D Lewis, J M Brewer*

## Recommendations

**1278** 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis

*E Nikiphorou, E J F Santos, A Marques, P Böhm, J W J Bijlsma, C I Daien, B A Esbensen, R J O Ferreira, G E Fragoulis, P Holmes, H McBain, G S Metsios, R H Moe, T A Stamm, A de Thurah, C Zabalan, L Carmona, A Bosworth*

**1286** EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis

*K Mankia, H J Siddle, A Kerschbaumer, D Alpizar Rodriguez, A I Catrina, J D Cañete, A P Cope, C I Daien, K D Deane, H El Gabalawy, A Finckh, V M Holers, M Koloumas, F Ometto, K Raza, C Zabalan, A van der Helm-van Mil, D van Schaardenburg, D Aletaha, P Emery*

**1299** EULAR recommendations for intra-articular therapies

*J Uson, S C Rodriguez-García, R Castellanos-Moreira, T W O'Neill, M Doherty, M Boesen, H Pandit, I Möller Parera, V Vardanyan, L Terslev, W U Kampen, M-A D'Agostino, F Berenbaum, E Nikiphorou, I A Pitsillidou, J de la Torre-Aboki, L Carmona, E Naredo*

## Epidemiology

**1306** Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

*U M Geisen, D K Berner, F Tran, M Sümbül, L Vullriede, M Ciripoi, H M Reid, A Schaffarzyk, A C Longardt, J Franzenburg, P Hoff, J H Schirmer, R Zeuner, A Friedrichs, A Steinbach, C Knies, R DH Markewitz, P J Morrison, S Gerdes, S Schreiber, B F Hoyer*

**1312** SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases

*D Simon, K Tascilar, F Fagni, G Krönke, A Kleyer, C Meder, R Atreya, M Leppkes, A E Kremer, A Ramming, M L Pachowsky, F Schuch, M Ronneberger, S Kleinert, A J Hueber, K Manger, B Manger, C Berking, M Stücherling, M F Neurath, G Schett*

**1317** Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2

*Y Braun-Moscovici, M Kaplan, M Braun, D Markovits, S Giryas, K Toledano, Y Tavor, K Dolnikov, A Balbir-Gurman*

**1322** Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression

*M Prendecki, C Clarke, H Edwards, S McIntyre, P Mortimer, S Gleeson, P Martin, T Thomson, P Randell, A Shah, A Singanayagam, L Lightstone, A Cox, P Kelleher, M Willicombe, S P McAdoo*

**MORE CONTENTS ►**



Member since 2008  
JM00004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>

- 1330** Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study  
*V Furer, T Eviatar, D Zisman, H Peleg, D Paran, D Levartovsky, M Zisapel, O Elalouf, I Kaufman, R Meidan, A Broyde, A Polachek, J Wollman, I Litinsky, K Meridor, H Nochomovitz, A Silberman, D Rosenberg, J Feld, A Haddad, T Gazzit, M Elias, N Higazi, F Kharouf, G Shefer, O Sharon, S Pel, S Nevo, O Elkayam*
- 1339** Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease  
*R H Haberman, R Herati, D Simon, M Samanovic, R B Blank, M Tuen, S B Korolov, R Atreya, K Tascilar, J R Allen, R Castillo, A R Cornelius, P Rackoff, G Solomon, S Adhikari, N Azar, P Rosenthal, P Izmirly, J Samuels, B Golden, S M Reddy, M F Neurath, S B Abramson, G Schett, M J Mulligan, J U Scher*
- 1345** SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity  
*D Mrak, S Tobudic, M Koblischke, M Graninger, H Radner, D Sieghart, P Hofer, T Perkmann, H Haslacher, R Thalhammer, S Winkler, S Blüml, K Stiasny, J H Aberle, J S Smolen, L X Heinz, D Aletaha, M Bonelli*
- 1357** Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases  
*R Spiera, S Jinich, D Jannat-Khah*
- 1359** Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report  
*B Golding, Y Lee, H Golding, S Khurana*
- 1361** Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response  
*F N Albach, G R Burmester, R Biesen*
- 1362** Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation  
*M T H F Janssen, S Ramiro, R B M Landewé, C Magro-Checa, R L M Mostard*
- 1364** Prospective study into COVID-19-like symptoms in patients with and without immune-mediated inflammatory diseases or immunomodulating drugs  
*L van Ouwkerke, A E van der Meulen-de Jong, M K Ninaber, Y K O Teng, T W J Huizinga, C F Allaart*
- 1365** Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases  
*T P-Y Chiang, C M Connolly, J A Ruddy, B J Boyarsky, J L Alejo, W A Werbel, A Massie, L Christopher-Stine, J Garonzik-Wang, D L Segev, J J Paik*
- 1352** Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City  
*M Barbhuiya, J M Levine, V P Bykerk, D Jannat-Khah, L A Mandl*
- 1354** SARS-CoV-2 vaccination after stem cell transplantation for scleroderma  
*D Rimar, G Slobodin, A Paz, I Henig, T Zuckerman*
- 1355** SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response  
*M M Bonelli, D Mrak, T Perkmann, H Haslacher, D Aletaha*

## Letters

- 1351** High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases  
*J A Ruddy, C M Connolly, B J Boyarsky, W A Werbel, L Christopher-Stine, J Garonzik-Wang, D L Segev, J J Paik*

## Electronic pages

- e156** Correspondence on 'EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs'  
*S Bugatti, S Balduzzi, L De Stefano, A Manzo, B Xoxi, L Bogliolo, S Monti, P Delvino, C Montecucco*
- e157** Response to: 'Correspondence on 'EULAR December 2020 View points on SARS-CoV-2 vaccination in patients with RMDs'' by Bugatti *et al*  
*J W J Bijlsma, on behalf of EULAR COVID-19 Task Force*

- e158** Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'  
*C Salviani, F Scolari, F Alberici*
- e159** Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'  
*G A Ramirez, E Della-Torre, L Moroni, M-R Yacoub, L Dagna, On behalf of the OSR-COVAX study group*
- e160** Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'  
*J Veenstra, J Wang, K McKinnon-Maksimowicz, T Liu, B Zuniga, I Hamzavi, L Zhou, Q-S Mi*
- e161** Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'  
*L Valor-Méndez, K Tascilar, D Simon, J Distler, A Kleyer, G Schett, J Rech*
- e162** Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'  
*T H Westhoff, F S Seibert, M Anft, A Blazquez-Navarro, S Skrzypczyk, A Doevelaar, B Hölzer, K Paniskaki, S Doff, B Wilde, O Witzke, J Braun, U Stervbo, N Babel*
- e163** Response to: 'Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'' by Westhoff *et al*  
*M Bonelli, D Aletaha*
- e164** Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli *et al*  
*C M Connolly, D Koenig, S N Ravi, A Azar, S Kant, M Dalal, J Duchon, P Seo, B Antiochos, J J Paik, D Geetha*
- e165** Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli *et al*  
*S H Chung, M Wener, A M Bays, H Rahbar, C Morishima, A B Bryan, S L Fink, S Cohen, N S Mani, A Chaudhary, G C Gardner*
- e166** Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli *et al*  
*M Benucci, A Damiani, M Infantino, M Manfredi, V Grossi, B Lari, F Li Gobbi, P Sarzi Puttini*
- e167** Response to: Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli *et al*  
*M Bonelli, D Aletaha*
- e168** Correspondence on 'SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists'  
*G Smerilli, E Cipolletta, E Moscioni, F Francioso, A M Risa, V Maccarrone, D Zompa, A Di Matteo, M Di Carlo, R De Angelis, F Salaffi, E Filippucci, W Grassi*
- e169** Response to: 'Correspondence on 'SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists'' by Smerilli *et al*  
*R Priori, G Pellegrino, S Colafrancesco, C Alessandri, F Ceccarelli, M Di Franco, V Ricciari, R Scrivo, A Sili Scavalli, F R Spinelli, F Conti*
- e170** Correspondence on 'Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries'  
*S Al Nokhatha, N MacEoin, R Conway*
- e171** Response to: 'Correspondence on 'Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries'' by Nokhatha *et al*  
*C DeJaco, J WJ Bijlsma, F Buttgerit*